CCXI - CCXI STOCK NEWS

ChemoCentryx (Nasdaq: CCXI) will host a virtual R&D Day on April 14, 2021, at 12:30 p.m. ET. The event includes a panel of key opinion leaders and patient testimonials focusing on ANCA-associated vasculitis and the company’s pipeline developments. Notable presenters include Dr. Thomas J. Schall and Dr. Peter A. Merkel. A live webcast will be available at this link, with an archive accessible shortly after the event. ChemoCentryx is advancing new therapies for inflammatory and autoimmune diseases.

ChemoCentryx (Nasdaq: CCXI) announced the appointment of Susan M. Kanaya to its Board of Directors, effective March 2, 2021. Kanaya, who has served as Executive Vice President and Chief Financial and Administrative Officer since October 2016, has significantly contributed to the company’s growth and financial stability. The CEO highlighted her pivotal role in achieving operational goals and enhancing shareholder value. Kanaya expressed her commitment to driving the company’s growth as it approaches its first commercial launch.

ChemoCentryx announces financial results for Q4 and FY 2020, reporting revenue of $4.4 million in Q4, down from $10 million in Q4 2019, yet a strong full-year revenue of $64.9 million, up from $36.1 million in 2019. Key highlights include the publication of the ADVOCATE trial results for avacopan in ANCA-associated vasculitis, with positive results indicating benefits over standard care. The company plans to advance avacopan in Phase III trials for Hidradenitis Suppurativa and C3 Glomerulopathy. With $460 million in cash and investments, they anticipate a cash usage of $145-$155 million in 2021.

ChemoCentryx, Inc. (Nasdaq: CCXI) has announced presentations by CEO Thomas J. Schall, Ph.D. at upcoming investor conferences. He will speak at the Raymond James 42nd Annual Institutional Investors Conference on March 3 at 2:10 p.m. ET, and at the H.C. Wainwright Global Life Sciences Conference starting March 9 at 7:00 a.m. ET. Webcasts will be available on the company’s website, with replays accessible for two weeks. ChemoCentryx specializes in developing treatments for inflammatory diseases, with its lead drug candidate, avacopan, under FDA review.

ChemoCentryx, Inc. (Nasdaq: CCXI) has appointed Tausif ('Tosh') Butt as Executive Vice President and Chief Operating Officer. Butt brings over 20 years of experience from leading pharmaceutical companies, including AstraZeneca. He will oversee operational functions and enhance the commercial infrastructure in anticipation of the launch of avacopan, currently under FDA review, with a PDUFA goal date of July 7, 2021. ChemoCentryx develops therapies for inflammatory and autoimmune diseases and has promising candidates in various stages of clinical development.

ChemoCentryx, Inc. (CCXI) will report its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. A conference call to discuss these results will be held at 5:00 p.m. ET on the same day. Participants can join by dialing (877) 303-8028 for domestic calls or (760) 536-5167 for international calls, using conference ID 8283128. The call will also be available as a live and archived audio webcast on their website for 14 days. ChemoCentryx focuses on developing new medications for inflammatory, autoimmune diseases, and cancer.

ChemoCentryx (Nasdaq: CCXI) announced the publication of results from the pivotal Phase III study, ADVOCATE, for avacopan, a treatment for ANCA-associated vasculitis. The study showed that avacopan led to remission at 26 weeks and sustained remission at 52 weeks, surpassing the results of the traditional treatment with prednisone. Notably, avacopan reduced the risk of relapse by 54% and improved kidney function significantly. The FDA is currently reviewing the NDA for avacopan with a decision expected by July 7, 2021.

ChemoCentryx, Inc. (Nasdaq: CCXI) announced that its CEO, Thomas J. Schall, Ph.D., will present at two upcoming investor events: the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 11:40 a.m. ET, and the H.C. Wainwright Virtual BioConnect Conference, with an on-demand presentation available from January 11. Additionally, a Clinical Trial Panel Discussion will take place on January 11 at 12:00 p.m. ET. Live webcasts and replays can be accessed on the company’s website. ChemoCentryx is developing therapies for inflammatory diseases and cancer, with its lead drug, avacopan, under review by FDA and EMA.

ChemoCentryx announced positive topline results from the ACCOLADE trial evaluating avacopan for C3 Glomerulopathy, showing statistically significant improvement in renal function (eGFR) over 26 weeks compared to placebo. Although the primary endpoint of disease activity did not show statistical significance, avacopan demonstrated a significant benefit in reducing fibrosis progression. The drug was well-tolerated, and discussions with regulatory agencies regarding its approval are planned. The results are promising for patients with this rare kidney disease, which currently has no approved therapies.